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Aim. To describe a case of toxic epidermal necrolysis (TEN) with ocular involvement treated with topical ophthalmic cyclosporine.
Case Presentation. A 20-year-old woman developed TEN following administration of carbamazepine that was prescribed for
epilepsy. Ophthalmic examination revealed bilateral pseudomembranous conjunctivitis. She was hospitalized in the intensive care
unit and treated with intravenous corticosteroid and immunoglobulin. Topical cyclosporine was used in combination with topical
corticosteroids for ocular surface disease. Following two months of ocular treatment, she recovered without any severe ocular
complication. Ocular examination at the four-month followup showed a 2mm of symblepharon in the lower fornix as the sole
pathologic ﬁnding. Conclusion. Topical ophthalmic cyclosporine may contribute to decrease the ophthalmic complications of TEN
and should be considered in the acute stage of the disease.
1.Introduction
Toxic epidermal necrolysis (TEN) is a rare idiosyncratic mu-
cocutaneous reaction with high mortality rates and is char-
acterized by high fever and widespread blistering exanthema
of macules. The incidence is 0.4 to 1.2 cases per million per
year in the general population. Destruction and detachment
o ft h ee p i d e r m i sa sw e l la se r o s i o n so fm u c o u sm e m b r a n e s
arethemainfeaturesofTEN,whichisassumedtobeinduced
by drugs. Ocular involvement in TEN includes blisters of the
conjunctival surface, and devastating ocular complications
such as permanent visual loss are commonly encountered
[1].
In eﬀorts to reduce ocular damage, immediate anti-in-
ﬂammatory and immunosuppressant therapies have been
considered due to the immune-related cytotoxic nature of
the disease. Topical corticosteroids have been the main agent
used for this purpose as well as systemic medication. Nev-
ertheless, ocular sequelae are still problematic in surviving
TEN patients.
Herein,wepresentacasewithTENinwhomtopicaloph-
thalmic cyclosporine was used, resulting in recovery without
any severe ocular complication.
2.CaseReport
A 20-year-old female was admitted to the emergency service
with a two-day history of generalized erythematous macu-
lopapular rash. Her medical history was positive for epilepsy.
Her neurologist had changed her medication from sodium
valproate to carbamazepine 5 days before. Her physical
examinationrevealedwidespreadredskinwithmaculopapu-
lar and vesiculobullous eruptions and rashes (Figure 1(a)).
More than 80% of the patient’s total body surface area
was involved in addition to the mucous membranes. The
patient was tachypneic (130/min), and her body temper-
ature was 38.6◦C. The ophthalmic examination revealed
vesiculobullous skin lesions of the eyelids. The conjunctiva
was hyperemic, and pseudomembranous conjunctivitis was
present bilaterally (Figures 1(b) and 1(c)). The cornea and
other anterior segment elements were normal.
The clinical diagnosis was consistent with TEN. The pa-
tient was hospitalized in the intensive care unit, and carba-
mazepine was discontinued immediately. Blood and urine
cultures were obtained and intravenous teicoplanin (1 ×
400mg) and methylprednisolone (60mg/day) treatment was
initiated the same day. The following day, intravenous2 Case Reports in Medicine
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Figure 1: (a) The face and upper trunk of 20-year-old toxic epi-
dermal necrolysis patient manifesting swollen and crusted lips,
blisters, and erosions of skin; (b, c) bilateral pseudomembranous
conjunctivitis.
immunoglobulin was started, and a total dose of 105g
(2g/kg) was given in divided doses for 5 days. Sedation was
performed using midazolam. Ophthalmic therapy included
daily removal of eyelid crusting and topical instillation of
preservative-freeartiﬁcialtears7 ×1,lomeﬂoxacin3 ×1,ﬂu-
orometholone 4 × 1, and ophthalmic cyclosporine 3 × 1.
Disease progression was halted on the 6th day of disease
onset, and systemic therapy was terminated on the 8th day.
Reepithelization was nearly complete by the 2nd week. She
was discharged from the hospital on the 16th day.
Topicalﬂuorometholoneandcyclosporinetreatmentwas
continued through the 2nd month. The ﬁnal ophthalmic
examination in the 4th month revealed bilateral visual acuity
of 20/20, clear cornea, Schirmer test value >15mm, and
only 2mm of symblepharon in the lower fornix laterally
(Figure 2).
3. Discussion
Toxic epidermal necrolysis (TEN) is believed to be an immu-
nologiccytotoxicreactionleadingtowidespreadapoptosisof
keratinocytes,withreportedmortalityratesofapproximately
25–35% [2]. As the risk of developing TEN is the highest
when the antiepileptic therapy has been recently initiated,
and subsequently declines within 8 weeks or more of admin-
istration, carbamazepine is supposed to be the causative
agent that induced TEN in our demonstrated case where she
was on carbamazepine therapy for ﬁve days [3].
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Figure 2:Ophthalmicexaminationatthefourthmonthpresenting,
(a, b) normal anterior segment features, (c) symblepharon forma-
tion in the lower fornix of the right eye.
Genetic susceptibility plays an important role in the pa-
thophysiology of TEN [4]. Immunopathologic studies have
demonstrated a clonal expansion of CD8+ cytotoxic T lym-
phocytes, and the production of proinﬂammatory and cos-
timulatory cytokines apparently plays a central role in TEN.
Itis now wellestablished thatin addition to severalapoptotic
pathways such as perforin/granzyme or Fas-Fas ligand, se-
cretory granulysin is also involved in the pathogenesis of
TEN. Furthermore, regulatory CD4+ CD25+ T cells have
been demonstrated to be potentially important in the pre-
vention of severe epidermal damage by reactive cytotoxic T
lymphocytes [5, 6].
Systemic drug therapies have been used to halt this ma-
lignant process in order to improve the disease outcome
by decreasing mortality rates. These drugs include systemic
steroids, thalidomide, intravenous immunoglobulin, cyclo-
phosphamide, tumor necrosis factor-alpha blockers, and cy-
closporine. Though some of these agents were reported to
have beneﬁcial eﬀects on the disease course, there are no re-
ports indicating a signiﬁcant eﬀect on reducing ocular com-
plications in frequency or severity [7].Case Reports in Medicine 3
Hence,medicaland/orsurgicallocaltreatmentismanda-
torytopreventocularcomplications[8].Conventionaltreat-
ment includes topical steroids, antibiotics, and tear substi-
tutes. Furthermore, immediate conjunctival adhesiolysis and
amniotic membrane grafting are the surgical interventions
aimed at reducing ocular morbidity.
In principle, ophthalmic therapy in TEN should primar-
ily focus on suppressing the inﬂammatory and destructive
reaction on the ocular surface. The pathologic process men-
tioned above seems to be initiated by cytotoxic T-cells.
Soluble interleukin-2 receptors (sIL-2Rs), which are consid-
ered a marker of T-cell activation, have been detected in
high levels in the blister ﬂuid of patients with TEN [9].
This ﬁnding addresses the participation of activated T lym-
phocytes or associated cytokines in the initial steps of the
disease.
At this point, cyclosporine could be a good candidate for
systemic and topical ophthalmic use as an immunosuppres-
santagentthatactsselectivelytosuppressT-cellimmunityby
inhibiting IL-2 expression and preventing proliferation and
activation of T lymphocytes.
Recently, in a relatively large group (n:29) of TEN/Stev-
ens-Johnson syndrome (SJS) patients, oral administration of
cyclosporinewasshowntostoptheprogressionofthedisease
in the majority of patients and contributed to the survival
[10].However,no data areavailableaboutits eﬀectonocular
disease.
Topical ophthalmic cyclosporine has found a large range
of indication in inﬂammatory-/immune-mediated ocular
surface diseases, particularly dry eye disease, severe allergic
keratoconjunctivitis, and corneal transplant surgery. TEN
is on the severe edge of this spectrum, and ophthalmic
cyclosporine may be a potential agent in the acute phase
management of TEN for limiting the destructive inﬂamma-
tion.
Previously, topical ophthalmic cyclosporine was used by
Shammasetal.intheacutestageofSJSandTENin8patients
[11]. While they reported preservation of good visual acuity
and an intact ocular surface, the role of cyclosporine is not
clear, as it had been used in combination with coverage of
the entire ocular surface with amniotic membrane.
In conclusion, cyclosporine use in the topical treatment
of ocular TEN disease may have beneﬁcial eﬀects in prevent-
ing ophthalmic complications. Further investigations need
to be conducted with larger series to draw a more deﬁnitive
conclusion.
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